{"id":17482,"date":"2023-07-03T07:19:19","date_gmt":"2023-07-03T05:19:19","guid":{"rendered":"http:\/\/mabdesign.fr\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/"},"modified":"2023-07-03T07:19:19","modified_gmt":"2023-07-03T05:19:19","slug":"delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/","title":{"rendered":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial."},"content":{"rendered":"

June, 20, 2023<\/strong>: DELPHARM and CREAPHARM announced today that they have combined their expertises to synergistically support
\nHMNC Brain Health, a global clinical-stage biopharmaceutical company pioneering the development of personalized
\ntherapies in psychiatry. On June 20, 2023, HMNC announced enrollement of the First Patient In (FPI) in Phase 2, PoC trial in more than 300 patients with Major Depressive Disorder (MDD) conducted in eight countries in Europe.
\nThis trial is a crucial component of the Nelivabon program, one of HMNC Brain Health’s flagship precision psychiatry programs,
\naimed at developing BH-200, a potent vasopressin V1b receptor antagonist, for improved treatment of patients with MDD who
\nhave underlying HPA-axis (Hypothalamus\u2010pituitary\u2010adrenal axis) dysfunction. Moreover, it will test the predictive capabilities
\nof the V1b polygenic score, which the company aims to eventually develop into a companion diagnostic for BH-200. To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

DELPHARM and CREAPHARM announced today that they have combined their expertises<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-17482","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members"],"yoast_head":"\nDELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign<\/title>\n<meta name=\"description\" content=\"DELPHARM and CREAPHARM announced today that they have combined their expertises\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign\" \/>\n<meta property=\"og:description\" content=\"DELPHARM and CREAPHARM announced today that they have combined their expertises\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-03T05:19:19+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial.\",\"datePublished\":\"2023-07-03T05:19:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\"},\"wordCount\":164,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\",\"name\":\"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2023-07-03T05:19:19+00:00\",\"description\":\"DELPHARM and CREAPHARM announced today that they have combined their expertises\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign","description":"DELPHARM and CREAPHARM announced today that they have combined their expertises","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign","og_description":"DELPHARM and CREAPHARM announced today that they have combined their expertises","og_url":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/","og_site_name":"MabDesign","article_published_time":"2023-07-03T05:19:19+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial.","datePublished":"2023-07-03T05:19:19+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/"},"wordCount":164,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/","url":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/","name":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial. - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2023-07-03T05:19:19+00:00","description":"DELPHARM and CREAPHARM announced today that they have combined their expertises","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/delpharm-creapharm-announced-they-have-successfully-joined-forces-to-better-serve-hmnc-brain-health-and-met-the-fpi-deadline-in-its-bh-200-03-european-phase-2-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"DELPHARM & CREAPHARM announced they have successfully joined forces to better serve HMNC Brain Health and met the FPI deadline in its BH-200-03 European phase 2 clinical trial."}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17482"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17482\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}